Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Key findings from this phase 2 obesity trial included: Mean weight reduction of up to approximately 24.2% at the highest dose (12 mg) after 48 weeks Dose-dependent reductions in body weight across all active treatment arms Significant reductions in waist circumference, blood pressure, and lipid parameters Improvements in fasting glucose and insulin resistance markers A separate phase 2 trial in adults with type 2 diabetes (published in 2023) demonstrated meaningful HbA1c reductions alongside substantial weight loss, suggesting potential dual utility in both obesity and glycaemic management
Retatrutides triple-agonist design builds on these advances by addressing both energy intake and energy expenditure
Obesity is a complex medical condition that affects how the body processes energy and is influenced by both the brain and hormones
Late 2025, exact date is unknown
Hope you could understand
No controlled GLOW trial establishes a results timeline
.png)
